BioMarin Pharmaceutical

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

• Revenue over the four quarters to June 30, 2026: $3.41 billion, up 11% from a year earlier.SEC EDGAR filings (XBRL)
• Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.74 billion, up 7.2% from a year earlier.SEC EDGAR filings (XBRL)
• Capital expenditure over the four quarters to June 30, 2026: $0.12 billion, up 71% from a year earlier.SEC EDGAR filings (XBRL)
• Latest earnings call or results release (August 6, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.80 of 1.Palanor Discourse
• Guidance in the last 90 days: 3 outlook figures raised, 0 lowered, 2 held.Guidance Ledger (8-K results releases)
• Latest annual report (filed February 26, 2026): 8 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
• Insiders were net sellers in Q3 2026: $1.2 million on the open market.SEC Form 4
• 565 institutional managers reported a position at June 30, 2026 (+6 on the quarter before).SEC Form 13F
• H-1B filings certified in Q2 2026: 4 (13 a year earlier).U.S. Department of Labor (OFLC)

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for BioMarin Pharmaceutical yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

In the news

Headlines that name BioMarin Pharmaceutical, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days

1 headlines

0% positive · 0% negative

90 days

1 headlines

0% positive · 0% negative

• Neutral
  BioMarin Pharmaceutical Names Cara Bauer EVP and Chief People Officer (BMRN)

  gurufocus.com · via Marketaux · Oct 5, 2026

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

1. Oct 20, 2026Lobbying
   Lobbying report (BIOMARIN PHARMACEUTICAL INC.)third_quarter 2026 · $0.2 million
2. Oct 20, 2026Lobbying
   Lobbying report (BGR GOVERNMENT AFFAIRS)third_quarter 2026 · $0.1 million
3. Oct 13, 2026Patent
   Patent granted: CNP Variants and Conjugates ThereofUS 12760079
4. Sep 30, 20268-K
   Material agreement signedItem 1.01
5. Sep 14, 20268-K
   Director or officer changeItem 5.02
6. Aug 31, 20268-K
   Material agreement signedItem 1.01
7. Aug 18, 20268-K
   Material agreement signedItem 1.01
8. Jul 20, 2026Lobbying
   Lobbying report (BIOMARIN PHARMACEUTICAL INC.)second_quarter 2026 · $0.3 million
9. Jul 20, 2026Lobbying
   Lobbying report (BIOMARIN PHARMACEUTICAL INC.)second_quarter 2026 · $0.3 million
10. Jul 20, 2026Lobbying
    Lobbying report (BIOMARIN PHARMACEUTICAL INC.)second_quarter 2026 · $0.3 million
11. Jul 20, 2026Lobbying
    Lobbying report (BGR GOVERNMENT AFFAIRS)second_quarter 2026 · $0.1 million
12. Jul 6, 2026Lobbying
    Lobbying report (VENN STRATEGIES)second_quarter 2017 · $0.0 million
13. Jun 30, 2026Private credit
    Loans held by business development companies (Biomarin Pharmaceutical Inc.)$9.3 million at cost
14. Jun 4, 20268-K
    Director or officer changeItem 5.02
15. Jun 4, 20268-K
    Shareholder vote resultsItem 5.07
16. Apr 27, 20268-K
    Material agreement signedItem 1.01
17. Apr 27, 20268-K
    Acquisition or sale completedItem 2.01
18. Apr 20, 2026Lobbying
    Lobbying report (BIOMARIN PHARMACEUTICAL INC.)first_quarter 2026 · $0.5 million
19. Feb 26, 202610-K
    Annual report (10-K)8 risk factors added, 0 removed
20. Feb 12, 20268-K
    Material agreement signedItem 1.01
21. Jan 6, 2026Patent
    Patent granted: Use of C-Type Natriuretic Peptide Variants to Treat Skeletal DysplasiaUS 12514906
22. Dec 19, 20258-K
    Material agreement signedItem 1.01
23. Dec 17, 20258-K
    Director or officer changeItem 5.02
24. Nov 6, 2025Trademark
    Trademark application: RARE CONNECTIONS
25. Nov 6, 2025Trademark
    Trademark application: RARE CONNECTIONS
26. Nov 6, 2025Trademark
    Trademark application: REAL SUPPORT FOR RARE JOURNEYS
27. Aug 11, 20258-K
    Director or officer changeItem 5.02
28. Aug 1, 20258-K
    Director or officer changeItem 5.02
29. May 22, 20258-K
    Director or officer changeItem 5.02
30. May 22, 20258-K
    Shareholder vote resultsItem 5.07
31. May 16, 20258-K
    Material agreement signedItem 1.01
32. Feb 25, 2025Patent
    Patent granted: C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia in ChildrenUS 12233106
33. Feb 24, 20258-K
    Director or officer changeItem 5.02
34. Feb 24, 202510-K
    Annual report (10-K)2 risk factors added, 3 removed
35. Feb 4, 2025Patent
    Patent granted: USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITISUS 12214015
36. Jan 7, 2025Patent
    Patent granted: MANUFACTURE OF ACTIVE HIGHLY PHOSPHORYLATED HUMAN LYSOSOMAL SULFATASE ENZYMES AND USES THEREOFUS 12188058
37. Feb 26, 202410-K
    Annual report (10-K)1 risk factors added, 2 removed

Peers

Companies in the same sector in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

Identity

SEC CIK

1048477

LEI

NSLL8ITTRR0J5HEMR848

Wikidata

Q4914632